Elipovimab Biosimilar - Research Grade

Human

HIV-1ï؟½

5mg/ml

IgG1 - lambda2

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

Blue ice

The HIV-1 envelope glycoprotein is the principal target of broadly neutralizing antibodies and a focal point of vaccine and antiviral immunity research. Our research-grade anti-HIV-1 recombinant monoclonal antibody is an unconjugated, non-therapeutic analog of elipovimab, provided for research use only (RUO). Produced to stringent in vivo standards, this ultra-pure, low-endotoxin preparation is available in scalable milligram (mg) to gram (g) quantities to support heavy-usage, high-throughput laboratories. It functions as a neutralizing reagent and reference control for in vitro virus-binding and neutralization assays, viral-entry screening, and in vivo models of HIV infection and immunity.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks